Recombinant human insulin-like growth factor I (rhIGF I) reduces hyperglycaemia in patients with extreme insulin resistance
Authors:
- 1 September 1991
- journal article
- case report
- Published by Springer Nature in Diabetologia
- Vol. 34 (9) , 675-679
Abstract
The syndrome of type A insulin resistance is encountered in young women and is characterized by glucose intolerance or frank diabetes mellitus, endogenous hyperinsulinism, insensitivity to insulin administration, acanthosis nigricans and virilization. The insulin resistance is due to reduced cellular insulin binding because of a lack of or defective binding sites and/or because the interaction with the tyrosine kinase of the β-subunit is hindered. This study was undertaken to find out whether hyperglycaemia in these patients may be influenced by the administration of recombinant human insulin-like growth factor I which exerts insulin like effects through the insulin receptor as well as the type 1 insulin-like growth factor I receptor. Recombinant human insulin-like growth factor I was intravenously administered in two subsequent doses of 100 μg/kg body weight to three women with type A insulin resistance. An immediate but slow fall of blood glucose was observed. The glucose disappearance rate was 28.0 μmol/min, i.e. considerably lower than that seen in healthy subjects. The markedly elevated insulin and C-peptide levels fell in a parallel manner to blood glucose but not to normal levels. The results show that recombinant human insulin-like growth factor I, presumably by reacting with the type 1 insulin-like growth factor receptor, can normalize serum glucose levels in patients with severe insulin resistance at least for several hours. We suggest that the potential of recombinant human insulin-like growth factor I to control hyperglycaemia in type A insulin resistant patients should be explored in more depth.Keywords
This publication has 29 references indexed in Scilit:
- Therapeutic potential of insulinlike growth factor iTrends in Endocrinology & Metabolism, 1990
- Insulin Receptor Structure and Function in Normal and Pathological ConditionsAnnual Review of Medicine, 1990
- Human Diabetes Associated with a Mutation in the Tyrosine Kinase Domain of the Insulin ReceptorScience, 1989
- Human Diabetes Associated with a Deletion of the Tyrosine Kinase Domain of the Insulin ReceptorScience, 1989
- Detection of an Alteration in the Insulin-Receptor Gene in a Patient with Insulin Resistance, Acanthosis Nigricans, and the Polycystic Ovary Syndrome (Type A Insulin Resistance)New England Journal of Medicine, 1988
- Short-Term Metabolic Effects of Recombinant Human Insulin-like Growth Factor I in Healthy AdultsNew England Journal of Medicine, 1987
- Insulin receptor biosynthesis in cultured lymphocytes from insulin-resistant patients.Journal of Clinical Investigation, 1985
- Insulin‐Like Growth Factors I and II: Some Biological Actions and Receptor Binding Characteristics of Two Purified Constituents of Nonsuppressible Insulin‐Like Activity of Human SerumEuropean Journal of Biochemistry, 1978
- Insulin and nonsuppressible insulin-like activity (NSILA-S) stimulate the same glucose transport system via two separate receptors in rat heartBiochemical and Biophysical Research Communications, 1977
- Radioimmunological determination of human C-peptide in serumDiabetologia, 1975